Navigation Links
Phase 3 Cystic Fibrosis Trial Results Presented at European Conference
Date:6/15/2009

SYDNEY, June 16 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) is pleased to announce that additional results of its recently completed international Phase III trial of Bronchitol in patients with cystic fibrosis have been presented at the 2009 European Cystic Fibrosis Conference in Brest, France.

The results were presented to the conference on Friday 12 June by Dr Diana Bilton of the Royal Brompton Hospital, London.

The trial was a multi-centre, randomised, double blind, placebo controlled, 26 week study, with an optional further 6 month open label uncontrolled period. It was conducted in 40 centres in the United Kingdom, Ireland, Australia and New Zealand.

The primary endpoint of the trial was to assess whether Bronchitol improves lung function as measured by a change in FEV1 when administered twice per day for six months.

The key secondary endpoint of the trial was to assess whether Bronchitol further improves lung function in patients already being treated with the most commonly used CF therapeutic, rhDNase. Additional endpoints included changes in the Forced Vital Capacity of the lung, pulmonary exacerbations and antibiotic use.

Safety evaluation included the incidence of adverse events and the microbiology of sputum samples.

    Clinical Results
    -- There was a clinically meaningful change from baseline (119mL) and
       placebo (93mL) at week 26 with Bronchitol for FEV1 (p<0.001).
       Importantly, treatment with Bronchitol showed an immediate and
       sustained improvement in lung function (FEV1) over the 26 weeks
       (p<0.001).
    -- For the subgroup of patients on concomitant rhDNase there was also a
       significant improvement in FEV1 from baseline (88mL) and from placebo
       (109mL) at we
'/>"/>
SOURCE  Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 Tooth decay is an epidemic ... signs of the disease. The World Health Organization says that ... of adults have cavities. What are the long-term effects of ... a strong connection between the oral bacterial imbalance and serious ... so rampant, yet it is also 100% preventable? Answer: there ...
(Date:5/16/2013)... ISPE announced today that ... the newly created position of Vice President of ... be responsible for stimulating ISPE’s revenue growth by ... Society’s Member-led and staff-driven business model, initiating integrated ... membership and product marketing. , “Barbara joins ISPE ...
(Date:5/16/2013)... In late 2012, Dr. Sarah Hart, of ... in China about Appearance Medicine . Although Dr. Hart ... first trip to lecture in China, and quite a different ... home to 12 and 7 million people respectively. Interest in ... this point in time. As Dr. Hart passed through the ...
(Date:5/16/2013)... May 16, 2013 Cambridge Healthtech Institute ... August 19-23, 2013 at the Renaissance Waterfront Hotel in ... provide a close-up look at the current strategies and ... bottom-line quality. Leaders in the field will reveal ... produce biopharmaceuticals with greater specificity and efficiency. , “In ...
Breaking Biology Technology:Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2
... Pharmaceuticals, the proprietary products division of a wholly owned ... PRX ), today announced that the U.S. Food and ... (NDA) for ondansetron orally dissolving film strip (ODFS). Strativa ... of nausea and vomiting associated with highly- and moderately-emetogenic ...
... AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: ... and oncology, today announced the opening of an extended ... for the treatment of benign prostatic hyperplasia (BPH), a ... million men in the U.S. alone. Sanofi-aventis U.S. LLC ...
... 10 It doesn,t take long after,you,ve polished off ... reminded of it in the restroom. Some people are ... urinating. The unmistakable olfactory,experience is caused by organic sulfur-containing ... our Podcast listeners on,Chemistry in our everyday life. , ...
Cached Biology Technology:Strativa's New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA 2Strativa's New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA 3AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 4AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 5BASF Podcast: The Chemical Reporter - Why Does Your Urine Smell so Different After You've Eaten Asparagus? 2BASF Podcast: The Chemical Reporter - Why Does Your Urine Smell so Different After You've Eaten Asparagus? 3
(Date:5/16/2013)... with ,scissor hand-like, claws in fossil records and has ... , The 505 million year old fossil called ... a distant ancestor of lobsters and scorpions, was named ... as Edward Scissorhands - a movie about an artificial ... for hands. , Kooteninchela deppi is ...
(Date:5/16/2013)... of genome-wide analysis (GWA), where the entirety of an ... mutations or variants which can cause health problems is ... it can also pose major ethical problems if used ... Human Genetics (ESHG) published on line today (16 May ... ., Many services based on whole genome and on ...
(Date:5/16/2013)... our pulses outside of the gym. But doctors use the ... , Zhenan Bao, a professor of chemical engineering at Stanford, ... and no wider than a postage stamp. The flexible skin-like ... sensitive enough to help doctors detect stiff arteries and cardiovascular ... continuously track heart health and provide doctors a safer method ...
Breaking Biology News(10 mins):Actor Johnny Depp immortalized in ancient fossil find 2European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 3
... , Monitoring the construction of wells, avoid over-exploiting cold ... extraction. These are the recommendations from the Polytechnic University ... the contamination of La Selva geothermal system, above all ... for its spa resorts and bottling plants, as well ...
... GAINESVILLE, Fla. --- The discovery of two new extinct ... on the history of the tropics, a region containing more ... important ecosystems. Appearing online this week in the ... published description of a fossil mammal discovered as part of ...
... to lead wreaks havoc in the brain, with consequences ... But the precise mechanism by which lead alters nerve ... New research led by Toms R. Guilarte, PhD, Leon ... Columbia University Mailman School of Public Health, and post-doctoral ...
Cached Biology News:Contamination of La Selva geothermal system in Girona, Spain 2Contamination of La Selva geothermal system in Girona, Spain 3UF scientists name new ancient camels from Panama Canal excavation 2UF scientists name new ancient camels from Panama Canal excavation 3In what ways does lead damage the brain? 2
PFK-2 car (P-17)...
... The product contains 5 ml Dynabeads Epoxy ... glycidyl ether (epoxy) reactive groups. Ideal for ... are absorbed hydrophobically on initial coupling with ... 2 and sulphydryll groups (SH)) occurring ...
LTBP-2 (7B10)...
... 2 Alzheimer's disease (AD) patients with ... mutations in the presenilin proteins (PSEN1; PSEN2) ... disease-linked mutations result in increased production of ... of amyloid deposits found in AD brains). ...
Biology Products: